Nature Communications (Apr 2023)

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells

  • Akimichi Inaba,
  • Zewen Kelvin Tuong,
  • Tian X. Zhao,
  • Andrew P. Stewart,
  • Rebeccah Mathews,
  • Lucy Truman,
  • Rouchelle Sriranjan,
  • Jane Kennet,
  • Kourosh Saeb-Parsy,
  • Linda Wicker,
  • Frank Waldron-Lynch,
  • Joseph Cheriyan,
  • John A. Todd,
  • Ziad Mallat,
  • Menna R. Clatworthy

DOI
https://doi.org/10.1038/s41467-023-37424-w
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Dysfunction of interleukin-10 producing regulatory B cells has been associated with the pathogenesis of autoimmune diseases, but whether regulatory B cells can be therapeutically induced in humans is currently unknown. Here we demonstrate that a subset of activated B cells expresses CD25, and the addition of low-dose recombinant IL-2 to in vitro stimulated peripheral blood and splenic human B cells augments IL-10 secretion. Administration of low dose IL-2, aldesleukin, to patients increases IL-10-producing B cells. Single-cell RNA sequencing of circulating immune cells isolated from low dose IL2-treated patients reveals an increase in plasmablast and plasma cell populations that are enriched for a regulatory B cell gene signature. The transcriptional repressor BACH2 is significantly down-regulated in plasma cells from IL-2-treated patients, BACH2 binds to the IL-10 gene promoter, and Bach2 depletion or genetic deficiency increases B cell IL-10, implicating BACH2 suppression as an important mechanism by which IL-2 may promote an immunoregulatory phenotype in B cells.